Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Cladribine"" wg kryterium: Temat


Tytuł :
COVID-19 in Cladribine-treated patient with multiple sclerosis.
Autorzy :
Haham N; Department of Neurology and Laboratory of Neuroimmunology, and the Agnes-Ginges Center for Neurogenetics, Hadassah Medical Center, Ein-Karem, Jerusalem 91120, Israel.
Vaknin-Dembinsky A; Department of Neurology and Laboratory of Neuroimmunology, and the Agnes-Ginges Center for Neurogenetics, Hadassah Medical Center, Ein-Karem, Jerusalem 91120, Israel. Electronic address: .
Pokaż więcej
Źródło :
Journal of neuroimmunology [J Neuroimmunol] 2021 Oct 15; Vol. 359, pp. 577690. Date of Electronic Publication: 2021 Aug 08.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
COVID-19/*immunology
Cladribine/*therapeutic use
Immunity, Humoral/*drug effects
Immunosuppressive Agents/*therapeutic use
Multiple Sclerosis, Relapsing-Remitting/*drug therapy
Multiple Sclerosis, Relapsing-Remitting/*immunology
COVID-19/diagnostic imaging ; Cladribine/pharmacology ; Drug Administration Schedule ; Humans ; Immunity, Humoral/physiology ; Immunosuppressive Agents/pharmacology ; Male ; Middle Aged ; Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Cladribine suppresses disease activity in neuromyelitis optica spectrum disorder: a 2-year follow-up study.
Autorzy :
Rejdak K; Department of Neurology, Medical University of Lublin, Lublin, Poland.
Papuć E; Department of Neurology, Medical University of Lublin, Lublin, Poland.
Pokaż więcej
Źródło :
European journal of neurology [Eur J Neurol] 2021 Sep; Vol. 28 (9), pp. 3167-3172. Date of Electronic Publication: 2021 Jul 26.
Typ publikacji :
Journal Article
MeSH Terms :
Cladribine*/therapeutic use
Neuromyelitis Optica*/drug therapy
Follow-Up Studies ; Humans ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Autorzy :
Kadia TM; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ravandi F; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Borthakur G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Konopleva M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
DiNardo CD; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Daver N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pemmaraju N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kanagal-Shamanna R; Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wang X; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Huang X; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pierce S; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rausch C; Department of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Burger J; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ferrajoli A; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jain N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Popat U; Department of Stem Cell Transplant, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Estrov Z; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Verstovsek S; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jabbour E; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Garcia-Manero G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kantarjian H; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2021 Aug 01; Vol. 96 (8), pp. 914-924. Date of Electronic Publication: 2021 May 26.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cladribine/*therapeutic use
Clofarabine/*therapeutic use
Cytarabine/*therapeutic use
Decitabine/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Cladribine/pharmacology ; Clofarabine/pharmacology ; Cytarabine/pharmacology ; Decitabine/pharmacology ; Humans ; Middle Aged ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Efficacy and safety of cladribine addition to induction treatment of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis.
Autorzy :
Pan Q; Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China.
Li J; Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China.
Pokaż więcej
Źródło :
Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 577-587.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cladribine/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cladribine/adverse effects ; Humans ; Induction Chemotherapy ; Leukemia, Myeloid, Acute/diagnosis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Therapy of 3 patients with Erdhiem-Chester disease with cladribin or cladribin in combination with cyclophosphamide. Case report and review of the therapy.
Autorzy :
Král Z
Řehák Z
Krejčí M
Koukalová R
Ševčíková S
Pour L
Krejčí M
Štork M
Sandecká V
Adam Z
Pokaż więcej
Transliterated Title :
Léčba tří pacientů s Erdheimovou-Chesterovou chorobou kladribinem, případně kombinací kladribinu a cyklofosfamidu a přehled léčby této nemoci.
Źródło :
Vnitrni lekarstvi [Vnitr Lek] 2021 Summer; Vol. 67 (3), pp. 157-164.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Cladribine*
Erdheim-Chester Disease*
Adult ; Cyclophosphamide ; Humans ; Interleukin 1 Receptor Antagonist Protein ; Remission Induction
Czasopismo naukowe
Tytuł :
Single-agent cladribine as an effective front-line therapy for adults with Langerhans cell histiocytosis.
Autorzy :
Goyal G; Division of Hematology-Oncology, University of Alabama at Birmingham, Birmingham, Alabama.; Research Collaborator, Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Abeykoon JP; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Hu M; Department of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, Minnesota.
Young JR; Department of Radiology, Mayo Clinic, Rochester, Minnesota.
Shah MV; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Bennani NN; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Call TG; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Hook CC; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Pardanani A; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Inwards DJ; Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Vassallo R; Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.
Ryu JH; Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota.
Tobin WO; Department of Neurology, Mayo Clinic, Rochester, Minnesota.
Koster MJ; Division of Rheumatology, Mayo Clinic, Rochester, Minnesota.
Davidge-Pitts CJ; Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Rochester, Minnesota.
Ravindran A; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Rech KL; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Go RS; Department of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, Minnesota.
Pokaż więcej
Corporate Authors :
Mayo Clinic-University of Alabama at Birmingham Histiocytosis Working Group
Źródło :
American journal of hematology [Am J Hematol] 2021 May 01; Vol. 96 (5), pp. E146-E150. Date of Electronic Publication: 2021 Feb 19.
Typ publikacji :
Letter; Research Support, N.I.H., Extramural
MeSH Terms :
Cladribine/*therapeutic use
Histiocytosis, Langerhans-Cell/*drug therapy
Adult ; Aged ; Cladribine/administration & dosage ; Cladribine/pharmacology ; Combined Modality Therapy ; Disease Progression ; Drug Evaluation ; Female ; Histiocytosis, Langerhans-Cell/diagnostic imaging ; Histiocytosis, Langerhans-Cell/physiopathology ; Histiocytosis, Langerhans-Cell/therapy ; Humans ; Kaplan-Meier Estimate ; MAP Kinase Signaling System/drug effects ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Mutation, Missense ; Point Mutation ; Positron Emission Tomography Computed Tomography ; Progression-Free Survival ; Proto-Oncogene Proteins B-raf/genetics ; Pulmonary Diffusing Capacity/drug effects ; Retrospective Studies ; Treatment Outcome ; Young Adult
Raport
Tytuł :
Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy.
Autorzy :
Przespolewski A; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Muppidi MR; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Department of Medicine, New York City Health + Hospitals, Bronx, NY, USA.
Freyer CW; Department of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Ji W; Department of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Cronin TL; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Thota S; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Griffiths EA; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Thompson JE; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Ontiveros EP; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.; Cancer Care Specialists of Illinois, Decatur, IL, USA.
Baron J; Department of Pharmacy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Elshoury A; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Wang ES; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
Pokaż więcej
Źródło :
Leukemia & lymphoma [Leuk Lymphoma] 2021 Jul; Vol. 62 (7), pp. 1778-1781. Date of Electronic Publication: 2021 Feb 16.
Typ publikacji :
Letter
MeSH Terms :
Cladribine*
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Cytarabine ; Humans ; Karyotype ; Mitoxantrone
Opinia redakcyjna
Tytuł :
Cladribine transfer into human milk: A case report.
Autorzy :
Datta P; Department of Pediatrics, Texas Tech University Health Sciences Center, Amarillo, TX, USA.
Ciplea AI; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany/Institute of Clinical Pharmacy and Pharmacotherapy, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Rewers-Felkins K; Department of Pediatrics, Texas Tech University Health Sciences Center, Amarillo, TX, USA.
Baker T; Department of Obstetrics and Gynecology, Texas Tech University Health Sciences Center, Amarillo, TX, USA.
Gold R; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
Hale TW; Department of Pediatrics, Texas Tech University Health Sciences Center, Amarillo, TX, USA.
Hellwig K; Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
Pokaż więcej
Źródło :
Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2021 Apr; Vol. 27 (5), pp. 799-801. Date of Electronic Publication: 2020 Jun 08.
Typ publikacji :
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cladribine*
Multiple Sclerosis, Relapsing-Remitting*
Breast Feeding ; Female ; Humans ; Immunosuppressive Agents ; Infant ; Lactation ; Milk, Human ; Mothers
Czasopismo naukowe
Tytuł :
[CLAG Regimen Composed of Continuous Intravenous Infusion of Cladribine in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia].
Autorzy :
Mi RH; Henan Cancer Hospital/The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, Henna Province, China.
Chen L; Henan Cancer Hospital/The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, Henna Province, China.
Yang HP; Department of Hematology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471000, Henan Province, China.
Wang XJ; Department of Hematology, The Third People's Hospital of Zhengzhou, Zhengzhou 450000, Henan Province, China.
Guo SL; Department of Hematology, Luoyang Central Hospital, Luoyang 471000, Henan Province, China.
Shi L; Department of Hematology, Second Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou 450000, Henan Province, China.
Yin QS; Henan Cancer Hospital/The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, Henna Province, China.
Wei XD; Henan Cancer Hospital/The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou 450008, Henna Province, China,E-mail: .
Pokaż więcej
Źródło :
Zhongguo shi yan xue ye xue za zhi [Zhongguo Shi Yan Xue Ye Xue Za Zhi] 2021 Apr; Vol. 29 (2), pp. 333-338.
Typ publikacji :
Journal Article
MeSH Terms :
Cladribine*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Adolescent ; Adult ; Antineoplastic Combined Chemotherapy Protocols ; Cytarabine/therapeutic use ; Female ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans ; Infusions, Intravenous ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
Autorzy :
Meuth SG; Abteilung für Neurologie, Universitätsklinikum Münster , Münster, Germany.
Bayas A; Klinik für Neurologie und Klinische Neurophysiologie, Universitätsklinikum Augsburg , Germany.
Kallmann B; Multiple Sklerose Zentrum Bamberg , Germany.
Kleinschnitz C; Klinik für Neurologie, Universitätsklinikum Essen , Germany.
Linker R; Klinik und Poliklinik für Neurologie, Universitätsklinikum Regensburg , Germany.
Rieckmann P; Abteilung für Neurologie, Medical Park Loipl , Germany.
Mäurer M; Klinik für Neurologie, Juliusspital Würzburg Klinikum Würzburg Mitte gGmbH , Germany.
Pokaż więcej
Źródło :
Expert opinion on pharmacotherapy [Expert Opin Pharmacother] 2020 Nov; Vol. 21 (16), pp. 1965-1969. Date of Electronic Publication: 2020 Jul 13.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Cladribine/*therapeutic use
Immunosuppressive Agents/*therapeutic use
Multiple Sclerosis/*drug therapy
Administration, Oral ; Cladribine/administration & dosage ; Cladribine/adverse effects ; Clinical Trials as Topic ; Drug Administration Schedule ; Drug Monitoring ; Expert Testimony ; Humans ; Immunosuppressive Agents/administration & dosage ; Immunosuppressive Agents/adverse effects ; Multiple Sclerosis/immunology ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Multiple Sclerosis, Relapsing-Remitting/immunology ; Practice Guidelines as Topic ; Recurrence ; Tablets ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Long-term follow-up of children with risk organ-negative Langerhans cell histiocytosis after 2-chlorodeoxyadenosine treatment.
Autorzy :
Barkaoui MA; French Reference Center for Langerhans Cell Histiocytosis, Trousseau Hospital, Paris, France.
Queheille E; French Reference Center for Langerhans Cell Histiocytosis, Trousseau Hospital, Paris, France.
Aladjidi N; Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Bordeaux, Bordeaux, France.
Plat G; Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Toulouse, Toulouse, France.
Jeziorski E; Department of Paediatric, Hôpital Arnaud de Villeneuve, Centre Hospitalo-Universitaire de Montpellier, Montpellier, France.
Moshous D; Department of Pediatric Immunology, Hematology and Rheumatology, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.; Institut Imagine, Paris University, Sorbonne-Paris-Cité, Paris, France.
Lambilliotte A; Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Lille, Lille, France.
Kebaili K; Department of Paediatric Oncology, Institut d'Hémato-Oncologie Pediatrique, Lyon, France.
Pacquement H; Pediatric, Adolescent and Young Adult Oncology Department, Institut Curie Medical Center, Paris, France.
Leverger G; Department of Pediatric Hematology and Oncology, Faculté de médecine, Trousseau Hospital, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Paris, France.
Mansuy L; Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Nancy, Vandœuvre-lès-Nancy, France.
Entz-Werlé N; Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Strasbourg, Strasbourg, France.
Bodet D; Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Cean, Cean, France.
Schneider P; Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Rouen, Rouen, France.
Pagnier A; Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Grenoble, Grenoble, France.
Lutun A; Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire d'Amiens, Amiens, France.
Gillibert-Yvert M; Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Tours, Tours, France.
Millot F; Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Poitiers, Poitiers, France.
Toutain F; Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Rennes, Rennes, France.
Reguerre Y; Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire Saint Denis de la Réunion, St Denis, France.
Thomas C; Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Nantes, Nantes, France.
Tazi A; Pneumology Department, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.; Université de Paris, INSERM U976, Paris, France.
Emile JF; EA4340, UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France.
Donadieu J; French Reference Center for Langerhans Cell Histiocytosis, Trousseau Hospital, Paris, France.; Department of Pediatric Hematology and Oncology, Faculté de médecine, Trousseau Hospital, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Paris, France.
Héritier S; French Reference Center for Langerhans Cell Histiocytosis, Trousseau Hospital, Paris, France.; Department of Pediatric Hematology and Oncology, Faculté de médecine, Trousseau Hospital, Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Paris, France.; EA4340, UVSQ, Université Paris-Saclay, Boulogne-Billancourt, France.
Pokaż więcej
Źródło :
British journal of haematology [Br J Haematol] 2020 Dec; Vol. 191 (5), pp. 825-834. Date of Electronic Publication: 2020 Jul 22.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Registries*
Cladribine/*administration & dosage
Histiocytosis, Langerhans-Cell/*drug therapy
Histiocytosis, Langerhans-Cell/*mortality
Adolescent ; Child ; Child, Preschool ; Cladribine/adverse effects ; Disease-Free Survival ; Female ; Follow-Up Studies ; France ; Histiocytosis, Langerhans-Cell/blood ; Humans ; Infant ; Lymphocyte Count ; Male ; Survival Rate
Czasopismo naukowe
Tytuł :
Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
Autorzy :
Wang H; Department of Hematological Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Wang L; Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, People's Republic of China.
Li C; Department of Hematological Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Wuxiao Z; Department of Hematology, Lymphoma and Myeloma Center, HMC Cancer Institute, The First Affiliated Hospital of Hainan Medical College, Haikou, Hainan, People's Republic of China.
Shao R; Department of Hematological Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Wang H; Department of Hematological Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Lu Y; Department of Hematological Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2020 Nov; Vol. 25 (11), pp. e1663-e1670. Date of Electronic Publication: 2020 Sep 21.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Aclarubicin*/therapeutic use
Cladribine*/therapeutic use
Cytarabine*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Female ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans ; Male ; Middle Aged ; Prospective Studies ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Biotransformation of cladribine by a nanostabilized extremophilic biocatalyst.
Autorzy :
Rivero CW; Laboratory of Sustainable Biotechnology (LIBioS), National University of Quilmes, Roque Sáenz Peña 352, Bernal, B1876BXD, Argentina; National Scientific and Technical Research Council (CONICET), Godoy Cruz 2290, CABA, C1425FQB, Argentina.
De Benedetti EC; Laboratory of Sustainable Biotechnology (LIBioS), National University of Quilmes, Roque Sáenz Peña 352, Bernal, B1876BXD, Argentina; National Scientific and Technical Research Council (CONICET), Godoy Cruz 2290, CABA, C1425FQB, Argentina.
Sambeth J; National Scientific and Technical Research Council (CONICET), Godoy Cruz 2290, CABA, C1425FQB, Argentina; Center for Research and Development in Applied Sciences 'Dr. Jorge J. Ronco', National University of La Plata, La Plata, Argentina.
Trelles JA; Laboratory of Sustainable Biotechnology (LIBioS), National University of Quilmes, Roque Sáenz Peña 352, Bernal, B1876BXD, Argentina; National Scientific and Technical Research Council (CONICET), Godoy Cruz 2290, CABA, C1425FQB, Argentina. Electronic address: .
Pokaż więcej
Źródło :
Journal of biotechnology [J Biotechnol] 2020 Nov 10; Vol. 323, pp. 166-173. Date of Electronic Publication: 2020 Aug 22.
Typ publikacji :
Journal Article
MeSH Terms :
Biotransformation*
Cladribine/*metabolism
Extremophiles/*physiology
Acrylic Resins ; Antineoplastic Agents/therapeutic use ; Biosynthetic Pathways ; Cladribine/therapeutic use ; Deoxyadenosines ; Geobacillus ; Leukemia, Hairy Cell/drug therapy ; Nanocomposites ; Temperature ; Thermobifida/growth & development ; Thermobifida/metabolism
SCR Organism :
Thermobifida alba
Czasopismo naukowe
Tytuł :
In vivo kinetics of the genotoxic and cytotoxic activities of cladribine and clofarabine.
Autorzy :
Quezada-Vidal J; Departamento de Biología, Instituto Nacional de Investigaciones Nucleares, Centro Nuclear, Carretera México-Toluca s/n, La Marquesa, Ocoyoacac, Estado de México, México.; Doctorado en Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana-Iztapalapa, Avenida San Rafael Atlixco 186, Ciudad de México, México.
Ortíz-Muñiz R; Doctorado en Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana-Iztapalapa, Avenida San Rafael Atlixco 186, Ciudad de México, México.
Cervantes-Ríos E; Doctorado en Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana-Iztapalapa, Avenida San Rafael Atlixco 186, Ciudad de México, México.
Cruz-Vallejo V; Departamento de Biología, Instituto Nacional de Investigaciones Nucleares, Centro Nuclear, Carretera México-Toluca s/n, La Marquesa, Ocoyoacac, Estado de México, México.
Morales-Ramírez P; Departamento de Biología, Instituto Nacional de Investigaciones Nucleares, Centro Nuclear, Carretera México-Toluca s/n, La Marquesa, Ocoyoacac, Estado de México, México.
Pokaż więcej
Źródło :
Environmental and molecular mutagenesis [Environ Mol Mutagen] 2020 Nov; Vol. 61 (9), pp. 922-927. Date of Electronic Publication: 2020 Jul 02.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*toxicity
Cladribine/*toxicity
Clofarabine/*toxicity
Micronuclei, Chromosome-Defective/*drug effects
Reticulocytes/*drug effects
Animals ; Antineoplastic Agents/blood ; Cladribine/blood ; Clofarabine/blood ; Kinetics ; Male ; Mice ; Mice, Inbred ICR ; Micronucleus Tests ; Reticulocytes/metabolism
Czasopismo naukowe
Tytuł :
Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS.
Autorzy :
Moser T; Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.; Department of Neurology, Multiple Sclerosis Center, Center of Clinical Neuroscience, Carl Gustav Carus University Hospital, Technische Universität Dresden, Dresden, Germany.
Schwenker K; Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.
Seiberl M; Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.
Feige J; Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.
Akgün K; Department of Neurology, Multiple Sclerosis Center, Center of Clinical Neuroscience, Carl Gustav Carus University Hospital, Technische Universität Dresden, Dresden, Germany.
Haschke-Becher E; Department of Laboratory Medicine, Paracelsus Medical University, Salzburg, Austria.
Ziemssen T; Department of Neurology, Multiple Sclerosis Center, Center of Clinical Neuroscience, Carl Gustav Carus University Hospital, Technische Universität Dresden, Dresden, Germany.
Sellner J; Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.; Department of Neurology, Klinikum rechts der Isar, Technische Universität München, München, Germany.; Department of Neurology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria.
Pokaż więcej
Źródło :
Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2020 Nov; Vol. 7 (11), pp. 2199-2212. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :
Journal Article
MeSH Terms :
Outcome Assessment, Health Care*
B-Lymphocyte Subsets/*drug effects
Cladribine/*pharmacology
Immunosuppressive Agents/*pharmacology
Multiple Sclerosis/*drug therapy
Multiple Sclerosis/*immunology
T-Lymphocyte Subsets/*drug effects
Adult ; Cladribine/administration & dosage ; Female ; Humans ; Immunosuppressive Agents/administration & dosage ; Male ; Middle Aged ; Multiple Sclerosis/blood ; Young Adult
Czasopismo naukowe
Tytuł :
Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
Autorzy :
Giovannoni G; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark St, Whitechapel, London, E1 2AT, UK. .
Comi G; Casa di Cura Privata del Policlinico, Università Vita-Salute San Raffaele, Milan, Italy.
Rammohan K; MS Research Center, University of Miami School of Medicine, Miami, FL, USA.
Rieckmann P; Department of Neurology, Medical Park Loipl and University of Erlangen, Erlangen, Germany.
Dangond F; EMD Serono Research and Development Institute, Inc., Billerica, MA, USA.
Keller B; The healthcare business of Merck KGaA, Darmstadt, Germany.
Jack D; Merck Serono Ltd (an affiliate of Merck KGaA, Darmstadt, Germany), Feltham, UK.
Vermersch P; Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France.
Pokaż więcej
Źródło :
Advances in therapy [Adv Ther] 2021 Sep; Vol. 38 (9), pp. 4975-4985. Date of Electronic Publication: 2021 Aug 09.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Multiple Sclerosis*
Multiple Sclerosis, Relapsing-Remitting*/drug therapy
Cladribine/therapeutic use ; Humans ; Immunosuppressive Agents/therapeutic use ; Recurrence ; Tablets
Czasopismo naukowe
Tytuł :
MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine.
Autorzy :
Seferoğlu M; Department of Neurology, Bursa Yüksek İhtisas Training and Research Hospital, University of Health Sciences, Bursa, Turkey. .
Ethemoğlu Ö; Department of Neurology, Harran University School of Medicine, Sanliurfa, Turkey.
Turan ÖF; Department of Neurology, Uludag University School of Medicine, Bursa, Turkey.
Siva A; Department of Neurology and MS Clinic, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Pokaż więcej
Źródło :
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2021 Sep; Vol. 42 (9), pp. 3533-3535. Date of Electronic Publication: 2021 Jun 24.
Typ publikacji :
Journal Article
MeSH Terms :
COVID-19*
Multiple Sclerosis*/drug therapy
Multiple Sclerosis*/epidemiology
Multiple Sclerosis, Relapsing-Remitting*/drug therapy
Cladribine/therapeutic use ; Humans ; Immunosuppressive Agents/therapeutic use ; Pandemics ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets - expert opinion on issues in clinical practice.
Autorzy :
Stangel M; Klinik für Neurologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany. Electronic address: .
Becker V; Neurologische Praxis Eppendorf, Kümmellstr. 1, D-20249 Hamburg, Germany. Electronic address: .
Elias-Hamp B; Birte Elias-Hamp, Praxis für Neurologie und Psychiatrie, Bengelsdorfstr. 5, D-22179 Hamburg, Germany. Electronic address: .
Havla J; Institute of Clinical Neuroimmunology, and Data Integration for Future Medicine (DIFUTURE) consortium, LMU Hospital, Ludwig-Maximilians Universität München, Munich, Germany. Electronic address: .
Grothe C; GFO-Kliniken Troisdorf, Wilhelm-Busch-Straße 9, D-53840 Troisdorf, Germany. Electronic address: .
Pul R; Klinik für Neurologie am Universitätsklinikum in Essen, Hufelandstr. 55, D-45147 Essen, Germany. Electronic address: .
Rau D; Nervenfachärztliche Gemeinschaftspraxis in Ulm, Pfauengasse 8, D-89073 Ulm, Germany. Electronic address: .
Richter S; MIND-MVZ Stuttgart, Charlottenstr. 14, D-70182 Stuttgart, Germany. Electronic address: .
Schmidt S; Neurologische Gemeinschaftspraxis Bonn, Gesundheitszentrum St. Johannes, Kölnstr. 54, D-53111 Bonn, Germany. Electronic address: .
Pokaż więcej
Źródło :
Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2021 Sep; Vol. 54, pp. 103075. Date of Electronic Publication: 2021 Jun 07.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Multiple Sclerosis*/drug therapy
Multiple Sclerosis, Relapsing-Remitting*/drug therapy
Cladribine ; Expert Testimony ; Female ; Humans ; Immunosuppressive Agents ; Neurologists ; Pregnancy ; Tablets
Czasopismo naukowe
Tytuł :
Severe skin reactions associated with cladribine in people with multiple sclerosis.
Autorzy :
Mateo-Casas M; The Blizard Institute (Neuroscience, Surgery & Trauma), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK; Department of Neurology, Hospital General Universitario de Castellón, Castellón de la Plana, Spain.
Reyes S; The Blizard Institute (Neuroscience, Surgery & Trauma), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK; Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK.
O'Toole EA; The Blizard Institute (Cell Biology & Cutaneous Research), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK.
De Trane S; The Blizard Institute (Neuroscience, Surgery & Trauma), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK; Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK.
Yildiz O; The Blizard Institute (Neuroscience, Surgery & Trauma), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK; Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK.
Allen-Philbey K; Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK.
Mathews J; Pathology and Pharmacy, The Royal London Hospital, Barts Health NHS Trust, London, UK.
Baker D; The Blizard Institute (Neuroscience, Surgery & Trauma), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK.
Giovannoni G; The Blizard Institute (Neuroscience, Surgery & Trauma), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK; Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK.
Schmierer K; The Blizard Institute (Neuroscience, Surgery & Trauma), Barts and The London School of Medicine and Dentistry, Queen Mary University of London, UK; Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK. Electronic address: .
Pokaż więcej
Źródło :
Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2020 Aug; Vol. 43, pp. 102140. Date of Electronic Publication: 2020 Apr 28.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Cladribine*/adverse effects
Immunosuppressive Agents*/adverse effects
Multiple Sclerosis*/drug therapy
Neoplasms*
Humans ; Recurrence
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies